Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Summary

Benralizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, benralizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.

Timeline

Start

2017-04-15

Primary completion

2019-07-25

Completion

2021-12

Publications

• Lee Y, Hojjati M. Benralizumab as a Potential Adjunctive Therapy in Eosinophilic Granulomatosis With Polyangiitis. J Clin Rheumatol. 2021 Dec 1;27(8S):S401-S402. doi: 10.1097/RHU.0000000000001419. No abstract available.

Drugs

Indications